The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Ji F, Li Z, Xue H, Liu L, Deng H

Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.

Southern medical journal 2011 Feb;104;140-2 — 2011 Feb — 140-2

Arora A, Vargas L, Kuzniar TJ

Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.

Journal of hospital medicine 2009 Sep;4;E45-6 — 2009 Sep — E45-6

Carson JJ, Gold LH, Barton AB, Biss RT

Fatality and interferon alpha for malignant melanoma.

Lancet (London, England) 1998 Oct 31;352;1443-4 — 1998 Oct 31 — 1443-4